[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07024498":3,"trial-entities:NCT07024498":135,"trial-summary:NCT07024498":138},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":28,"primary_purpose":13,"phases":29,"enrollment_info":31,"interventions":34,"primary_outcomes":40,"secondary_outcomes":45,"sex":56,"minimum_age":57,"maximum_age":58,"healthy_volunteers":14,"eligibility_criteria":59,"std_ages":64,"locations":68,"central_contacts":121,"overall_officials":128,"references":133,"see_also_links":134},"NCT07024498","2284130","Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment","RECRUITING","2029-08-01","2026-06","2026-06-12","2025-11-01","University of California, Davis","OTHER",false,"The main purpose of this stepped wedge trial will be to test the impact of a bundle of implementation strategies designed to improve ED-outpatient care coordination on long-term buprenorphine retention among adult patients who start buprenorphine for opioid use disorder in a hospital emergency department (ED) and then are referred for continued outpatient buprenorphine treatment after they leave the ED. Our hypothesis is that adopting the bundle of implementation strategies will be associated with subsequent increases in:\n\nA) Cumulative number of days with active buprenorphine prescription at 3, 6, and 12 months after patients' initial ED visit (6 months = primary outcome)\n\nB) Proportion of patients with active buprenorphine prescriptions without gaps in buprenorphine coverage of more than 7 days at 3, 6, and 12 months after patients' initial ED visit\n\nC) Proportion of patients who fill at least 1 outpatient buprenorphine prescription within 30 days of their ED visit\n\nD) Clinician reported quality of ED-outpatient care coordination and care transitions","Buprenorphine is a highly effective but underused medication for opioid use disorder that reduces cravings and decreases overdose risk. Starting buprenorphine for opioid use disorder in emergency departments (EDs) is recognized as a best clinical practice in the US. However, effective strategies to help patients sustain buprenorphine treatment after they leave the ED are urgently needed. To increase access to buprenorphine treatment, California established California Bridge, a state-funded program that offers same-day buprenorphine initiation plus referral to outpatient opioid use disorder treatment for patients. However, suboptimal ED-outpatient care coordination is a common barrier to buprenorphine retention. During a prior study, we identified a bundle of implementation strategies designed to improve ED-outpatient care coordination for patients who start buprenorphine for opioid use disorder in the ED. In this hybrid effectiveness-implementation study, the research team will work with core clinical teams at 12 sites (4 EDs and 8 outpatient clinics \\[2 clinics per ED\\]) to implement a bundle of implementation strategies at each site. Implementation will occur over a 12 month period (\\~3 months per site). Patient cohorts will be identified through electronic health record query reports. Data from eligible patients will then be abstracted from the electronic health record at each hospital. Changes in care coordination will be assessed using clinician surveys. Treatment outcomes will be assessed using buprenorphine prescription records obtained from California's prescription drug monitoring program linked to electronic health record data at the patient level. Study results will be used to develop an implementation blueprint that hospitals in California and across the US can use to improve opioid use disorder treatment outcomes for patients who start buprenorphine in hospital EDs.",[18],"Opioid Use Disorder",[20,21,22,23,24,25,26,27],"emergency department","opioid use disorder","care coordination","implementation science","hybrid effectiveness-implementation","multiteam systems","buprenorphine","stepped wedge","INTERVENTIONAL",[30],"NA",{"count":32,"type":33},3492,"ESTIMATED",[35],{"type":13,"name":36,"description":37,"armGroupLabels":38},"care coordination implementation strategies","The intervention will be a bundle of implementation strategies developed during a prior study and informed by the multi-team systems framework. Core implementation strategies are expected to include a standardized ED substance use navigator note (with education and billing support), a mechanism for sharing PHI information across ED-clinic pairs that use different electronic health record systems, an improved ability for patients to directly contact EDs and clinics, ensuring ED and outpatient teams mutually understand each other roles, implementing procedures to increase capacity for same-day outpatient buprenorphine refills, and interactive problem solving with an external facilitation team. Strategies will be adapted to local contexts at each site.",[39],"Hospital ED and 2 associated outpatient clinics that provide buprenorphine treatment",[41],{"measure":42,"description":43,"timeFrame":44},"buprenorphine treatment (continuous)","Cumulative number of days with active buprenorphine prescription after initial ED visit","6 months",[46,48,52],{"measure":42,"description":43,"timeFrame":47},"3 months, 12 months",{"measure":49,"description":50,"timeFrame":51},"buprenorphine retention (binary)","Proportion of patients with active buprenorphine prescriptions after initial ED visit without a gap in buprenorphine coverage of more than 7 days","3 months, 6 months, 12 months",{"measure":53,"description":54,"timeFrame":55},"outpatient buprenorphine initiation","Proportion of patients who fill at least 1 outpatient buprenorphine prescription within 30 days of their ED visit","30 days","ALL","14 Years",null,{"inclusion":60,"exclusion":62,"raw_text":63},[61],"patients who start buprenorphine for opioid use disorder at a participating ED",[],"Inclusion Criteria:\n\n* patients who start buprenorphine for opioid use disorder at a participating ED",[65,66,67],"CHILD","ADULT","OLDER_ADULT",[69,85,97,109],{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":75,"contacts":76,"geoPoint":82},"El Centro Regional Medical Center Emergency Department","NOT_YET_RECRUITING","El Centro","California","92243","United States",[77],{"name":78,"role":79,"phone":80,"email":81},"Rahul Nene, MD PhD","CONTACT","760-339-7100","rnene@health.ucsd.edu",{"lat":83,"lon":84},32.792,-115.56305,{"facility":86,"status":71,"city":87,"state":73,"zip":88,"country":75,"contacts":89,"geoPoint":94},"University of California Irvine Emergency Department","Irvine","92868",[90],{"name":91,"role":79,"phone":92,"email":93},"Bharath Chakravarthy, MD","714-456-7890","bchakrav@hs.uci.edu",{"lat":95,"lon":96},33.66946,-117.82311,{"facility":98,"status":7,"city":99,"state":73,"zip":100,"country":75,"contacts":101,"geoPoint":106},"Marshall Medical Center Emergency Department","Placerville","95667",[102],{"name":103,"role":79,"phone":104,"email":105},"Arianna Campbell, PA-C","530-409-7890","asampson@marshallmedical.org",{"lat":107,"lon":108},38.72963,-120.79855,{"facility":110,"status":7,"city":111,"state":73,"zip":112,"country":75,"contacts":113,"geoPoint":118},"University of California Davis Emergency Department","Sacramento","95817",[114],{"name":115,"role":79,"phone":116,"email":117},"Marykate Miller, MPH","916-734-2877","mkemiller@health.ucdavis.edu",{"lat":119,"lon":120},38.58157,-121.4944,[122,124],{"name":123,"role":79,"phone":116,"email":117},"Marykate MIller, MPH",{"name":125,"role":79,"phone":126,"email":127},"Stephen G Henry, MD MSc","916-734-7391","sghenry@health.ucdavis.edu",[129,131],{"name":125,"affiliation":12,"role":130},"PRINCIPAL_INVESTIGATOR",{"name":132,"affiliation":12,"role":130},"Aimee K Moulin, MD MAS",[],[],{"nct_id":4,"conditions":136,"biomarkers":137},[18],[],{"nct_id":4,"found":139,"summary":140,"prompt_version":150},true,{"design":141,"status":142,"heading":143,"summary":144,"follow_up":145,"word_count":146,"commitments":147,"compensation":148,"drugs_mentioned":149},"This is an interventional study planning to enroll 3492 participants. It is a 'stepped wedge' design, meaning the new care coordination strategies will be introduced at different times to different sites.","completed","Improving Buprenorphine Care After Emergency Department Visits","This study is looking at ways to help people who start buprenorphine (a medication for opioid use disorder) in the emergency room (ED) continue their treatment after they leave. Researchers are testing a set of strategies to improve how EDs and outpatient clinics work together to coordinate care. The goal is to see if these strategies help patients stay on buprenorphine treatment for longer. You might be able to join if you are 14 years or older and start buprenorphine for opioid use disorder in a participating ED. The main way they will measure success is by looking at how many days patients have an active buprenorphine prescription at 6 months after their ED visit. The current status of this study is unclear.","Researchers will track the cumulative number of days you have an active buprenorphine prescription for up to 12 months after your initial ED visit.",123,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]